

Serial No.: 08/873,601
Filed: June 12, 1997

Insert the Sequence Listing as pages 58-68.

Renumber the Claims as pages 69-72.

Renumber the Abstract as page 73.

In the Claims:

1. (Amended) A cell containing a composition comprising:
a) an [exogeneous]exogenous scaffold having no enzymatic activity and
comprising at least a first binding site and a second binding site; and
b) at least a first and a second enzyme, wherein at least one of said enzymes is
heterologous to said cell;
wherein said first enzyme is bound to said first binding site and said second enzyme is
bound to said second binding site.
2. (Amended) A cell containing a composition comprising:
a) nucleic acid encoding an [exogeneous]exogenous scaffold having no enzymatic
activity and comprising at least a first binding site and a second binding site; and
b) nucleic acid encoding at least a first and a second enzyme, wherein at least one
of said enzymes is heterologous to said cell;
wherein said first enzyme is capable of being bound to said first binding site and said
second enzyme is capable of being bound to said second binding site.
8. (Amended) A cell according to claim 1 or 2, further comprising
c) an [exogeneous]exogenous bioactive agent precursor.

Please add the following new claims:

- 27. A cell according to claim 1 or 2, wherein said cell is a mammalian cell.
28. A cell according to claim 1 or 2, wherein said scaffold is linear.
29. A cell according to claim 1 or 2, wherein said scaffold is circular.

Serial No.: 08/873,601
Filed: June 12, 1997

30. A cell according to claim 1 or 2, wherein said scaffold is branched.

31. A cell according to claim 1 or 2, wherein said scaffold further comprises a fusion partner.

32. A cell according to claim 1 or 2, wherein at least one of said enzymes further comprises a fusion partner.

33. A cell according to claim 31, wherein said fusion partner is a presentation structure.

34. A cell according to claim 31, wherein said fusion partner is a targeting sequence.

35. A cell according to claim 31, wherein said fusion partner is a rescue sequence.

36. A cell according to claim 31, wherein said fusion partner is a stability sequence.

37. A cell according to claim 31, wherein said fusion partner is a linker sequence.

38. A cell according to claim 32, wherein said fusion partner is a presentation structure.

39. A cell according to claim 32, wherein said fusion partner is a targeting sequence.

40. A cell according to claim 32 wherein said fusion partner is a rescue sequence.

41. A cell according to claim 32, wherein said fusion partner is a stability sequence.

42. A cell according to claim 32, wherein said fusion partner is a linker sequence.--

REMARKS

Claims 1-8 and 27 - 42 are pending. Claims 1-8 have been examined on their merits. An Appendix of the claims is attached for the Examiner's convenience. The amendments to the specification are to comply with sequence disclosure requirements